Galactosylated trimethyl chitosan-cysteine nanoparticles loaded with Map4k4 siRNA for targeting activated macrophages

Biomaterials

Volumn 34, Issue 14, 2013, Pages 3667-3677

  Zhang, Jing ^a   Tang, Cui ^a   Yin, Chunhua ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Chitosan derivate nanoparticles; Galactosylated modification; Oral administration; SiRNA; Targeted gene delivery; Ulcerative colitis

Indexed keywords

GALACTOSYLATED MODIFICATION; ORAL ADMINISTRATION; SIRNA; TARGETED GENE DELIVERY; ULCERATIVE COLITIS;

AMINO ACIDS; DISEASES; ENZYMES; GELATION; GENE TRANSFER; HYALURONIC ACID; MACROPHAGES; MOLECULAR BIOLOGY; NANOPARTICLES; STABILITY; ZETA POTENTIAL;

CHITOSAN;

CHITOSAN; CYSTEINE NANOPARTICLE; GALACTOSYLATED TRIMETHYL CHITOSAN; HYALURONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE KINASE 4 SMALL INTERFERING RNA; NANOPARTICLE; SMALL INTERFERING RNA; TRIPOLYPHOSPHATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL STRUCTURE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; GELATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; ULCERATIVE COLITIS; WEIGHT REDUCTION; ZETA POTENTIAL;

ANIMALS; CELL LINE; CHITOSAN; CYSTEINE; MACROPHAGES; MALE; MICE; MICE, INBRED C57BL; NANOPARTICLES; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875258221     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.01.079     Document Type: Article

References (33)

1. Laroui H., Wilson D.S., Dalmasso G., Salaita K., Murthy N., Sitaraman S.V., et al. Nanomedicine in GI. Am J Physiol-Gastr L 2011, 300:G371-G383.
2. Papadakis K.A., Targan S.R. Role of cytokines in the pathogenesis of inflammatory bowel disease. Annu Rev Med 2000, 51:289-298.
3. D'Haens G. Anti-TNF therapy for Crohn's disease. Curr Pharm Design 2003, 9:289-294.
4. Singha K., Namgung R., Kim W.J. Polymers in small-interfering RNA delivery. Nucleic Acid Ther 2011, 21:133-147.
5. Howard K.A., Paludan S.R., Behlke M.A., Besenbacher F., Deleuran B., Kjems J. Chitosan/siRNA nanoparticle-mediated TNF-α knockdown in peritoneal macrophages for anti-inflammatory treatment in a murine arthritis model. Mol Ther 2009, 17:162-168.
6. Aouadi M., Tesz G.J., Nicoloro S.M., Wang M.X., Chouinard M., Soto E., et al. Orally delivered siRNA targeting macrophage Map4k4 suppresses systemic inflammation. Nature 2009, 458:1180-1184.
7. Machida N., Umikawa M., Takei K., Sakima N., Myagmar B.E., Taira K., et al. Mitogen-activated protein kinase kinase kinase kinase 4 as a putative effector of Rap2 to activate the c-Jun N-terminal kinase. J Biol Chem 2004, 279:15711-15714.
8. van Vliet S.J., Saeland E., van Kooyk Y. Sweet preferences of MGL: carbohydrate specificity and function. Trends Immunol 2008, 29:83-90.
9. Coombs P.J., Taylor M.E., Drickamer K. Two categories of mammalian galactose-binding receptors distinguished by glycan array profiling. Glycobiology 2006, 16:1C-7C.
10. Zuo L.S., Huang Z., Dong L., Xu L.Q., Zhu Y., Zeng K., et al. Targeting delivery of anti-TNF alpha oligonucleotide into activated colonic macrophages protects against experimental colitis. Gut 2010, 59:470-479.
11. Morishita M., Peppas N.A. Is the oral route possible for peptide and protein drug delivery?. Drug Discov Today 2006, 11:905-910.
12. O'Neill M.J., Bourre L., Melgar S., O'Driscoll C.M. Intestinal delivery of non-viral gene therapeutics: physiological barriers and preclinical models. Drug Discov Today 2011, 16:203-218.
13. Dehousse V., Garbacki N., Jaspart S., Castagne D., Piel G., Colige A., et al. Comparison of chitosan/siRNA and trimethylchitosan/siRNA complexes behaviour in vitro. Int J Biol Macromol 2010, 46:342-349.
14. Kean T., Roth S., Thanou M. Trimethylated chitosans as non-viral gene delivery vectors: cytotoxicity and transfection efficiency. J Control Release 2005, 103:643-653.
15. Bernkop-Schnurch A. Thiomers: a new generation of mucoadhesive polymers. Adv Drug Deliver Rev 2005, 57:1569-1582.
16. Park I.K., Yang J., Jeong H.J., Bom H.S., Harada I., Akaike T., et al. Galactosylated chitosan as a synthetic extracellular matrix for hepatocytes attachment. Biomaterials 2003, 24:2331-2337.
17. Yin L.C., Ding J.Y., He C.B., Cui L.M., Tang C., Yin C.H. Drug permeability and mucoadhesion properties of thiolated trimethyl chitosan nanoparticles in oral insulin delivery. Biomaterials 2009, 30:5691-5700.
18. Jiang H.L., Kwon J.T., Kim E.M., Kim Y.K., Arote R., Jere D., et al. Galactosylated poly(ethylene glycol)-chitosan-graft-polyethylenimine as a gene carrier for hepatocyte-targeting. J Control Release 2008, 131:150-157.
19. Wilson D.S., Dalmasso G., Wang L.X., Sitaraman S.V., Merlin D., Murthy N. Orally delivered thioketal nanoparticles loaded with TNF-α-siRNA target inflammation and inhibit gene expression in the intestines. Nat Mater 2010, 9:923-928.
20. Laroui H., Theiss A.L., Yan Y.T., Dalmasso G., Nguyen H.T.T., Sitaraman S.V., et al. Functional TNF alpha gene silencing mediated by polyethyleneimine/TNF alpha siRNA nanocomplexes in inflamed colon. Biomaterials 2011, 32:1218-1228.
21. McLaren W., Anikijenko P., Barkla D., Delaney P., King R. In vivo detection of experimental ulcerative colitis in rats using fiberoptic confocal imaging (FOCI). Digest Dis Sci 2001, 46:2263-2276.
22. Bayat A., Dorkoosh F.A., Dehpour A.R., Moezi L., Larijani B., Junginger H.E., et al. Nanoparticles of quaternized chitosan derivatives as a carrier for colon delivery of insulin: ex vivo and in vivo studies. Int J Pharm 2008, 356:259-266.
23. Zhao X., Yin L.C., Ding J.Y., Tang C., Gu S.H., Yin C.H., et al. Thiolated trimethyl chitosan nanocomplexes as gene carriers with high in vitro and in vivo transfection efficiency. J Control Release 2010, 144:46-54.
24. Wang Q., Zhang L., Hu W., Hu Z.H., Bei Y.Y., Xu J.Y., et al. Norcantharidin-associated galactosylated chitosan nanoparticles for hepatocyte-targeted delivery. Nanomed Nanotechnol 2010, 6:371-381.
25. Janes K.A., Calvo P., Alonso M.J. Polysaccharide colloidal particles as delivery systems for macromolecules. Adv Drug Deliver Rev 2001, 47:83-97.
26. Ravina M., Cubillo E., Olmeda D., Novoa-Carballal R., Fernandez-Megia E., Riguera R., et al. Hyaluronic acid/chitosan-g-poly(ethylene glycol) nanoparticles for gene therapy: an application for pDNA and siRNA delivery. Pharm Res 2010, 27:2544-2555.
27. Berger J., Reist M., Mayer J.M., Felt O., Gurny R. Structure and interactions in chitosan hydrogels formed by complexation or aggregation for biomedical applications. Eur J Pharm Biopharm 2004, 57:35-52.
28. Bouzakri K., Ribaux P., Halban P.A. Silencing mitogen-activated protein 4 kinase 4 (MAP4K4) protects beta cells from tumor necrosis factor-alpha-induced decrease of IRS-2 and inhibition of glucose-stimulated insulin secretion. J Biol Chem 2009, 284:27892-27898.
29. Tahara K., Samura S., Tsuji K., Yamamoto H., Tsukada Y., Bando Y., et al. Oral nuclear factor-kappa B decoy oligonucleotides delivery system with chitosan modified poly(D, L-lactide-co-glycolide) nanospheres for inflammatory bowel disease. Biomaterials 2011, 32:870-878.
30. Lamprecht A., Schafer U., Lehr C.M. Size-dependent bioadhesion of micro- and nanoparticulate carriers to the inflamed colonic mucosa. Pharm Res 2001, 18:788-793.
31. Bouzakri K., Zierath J.R. MAP4K4 gene silencing in human skeletal muscle prevents tumor necrosis factor-alpha-induced insulin resistance. J Biol Chem 2007, 282:7783-7789.
32. Guntur K.V.P., Guilherme A., Xue L.T., Chawla A., Czech M.P. Map4k4 negatively regulates peroxisome proliferator-activated receptor (PPAR) gamma protein translation by suppressing the mammalian target of rapamycin (mTOR) signaling pathway in cultured adipocytes. J Biol Chem 2010, 285:6595-6603.
33. Tesz G.J., Aouadi M., Prot M., Nicoloro S.M., Boutet E., Amano S.U., et al. Glucan particles for selective delivery of siRNA to phagocytic cells in mice. Biochem J 2011, 436:351-362.